RedHill Biopharma Ltd.
-20.2% · 90d
$1.03
+0.01 (+0.49%)
News
(1)April 2026
RDHL Opaganib preclinical data show promise for neuroblastoma and TNBC
RDHLRedHill Biopharma Ltd.
# 📄 What This Document Is 📰 This filing is a Form 6-K, a document required by the U.S. Securities and Exchange Commission (SEC) for foreign private issuers like RedHill Biopharma Ltd. 🌍. Essentially, it acts like a mandatory update to keep U.S. investors informed about the company's activities.
Read summaryView on SEC EDGAR
Peers in Drug Manufacturers - Specialty & Generic
TAK#1
Takeda Pharmaceutical Company Limited
$57.78B-1.07%
ZTS#2
Zoetis Inc.
$50.46B+0.20%
HLN#3
Haleon plc
$43.61B+0.40%
TEVA#4
Teva Pharmaceutical Industries Limited
$36.05B+1.44%
UTHR#5
United Therapeutics Corporation
$25.19B-1.19%
VTRS#6
Viatris Inc.
$15.85B+0.29%
RGC#7
Regencell Bioscience Holdings Limited
$13.93B-2.46%
NBIX#8
Neurocrine Biosciences, Inc.
$13.21B-1.13%
ELAN#9
Elanco Animal Health Incorporated
$11.66B-0.59%
RDY#10
Dr. Reddy's Laboratories Limited
$10.92B+0.15%